150 related articles for article (PubMed ID: 31855264)
1. Evaluation of target attainment of oral posaconazole suspension in immunocompromised children.
Lai T; Alffenaar JW; Kesson A; Bandodkar S; Roberts JA
J Antimicrob Chemother; 2020 Mar; 75(3):726-729. PubMed ID: 31855264
[TBL] [Abstract][Full Text] [Related]
2. A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication.
Elkayal O; Spriet I; Uyttebroeck A; Colita A; Annaert P; Allegaert K; Smits A; Van Daele R; Dreesen E
Ther Drug Monit; 2021 Aug; 43(4):512-518. PubMed ID: 33560094
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
Liebenstein TK; Widmer KM; Fallon MJ
J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
[TBL] [Abstract][Full Text] [Related]
5. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
Geist MJP; Egerer G; Mikus G; Blank A; Hohmann N; Heinz WJ; Carls A
Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):56-61. PubMed ID: 29989301
[TBL] [Abstract][Full Text] [Related]
6. Posaconazole in immunocompromised pediatric patients.
Vicenzi EB; Cesaro S
Expert Rev Anti Infect Ther; 2018 Jul; 16(7):543-553. PubMed ID: 29912581
[TBL] [Abstract][Full Text] [Related]
7. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed-release tablet and intravenous posaconazole.
Bernardo V; Miles A; Fernandez AJ; Liverman R; Tippett A; Yildirim I
Pediatr Transplant; 2020 Sep; 24(6):e13777. PubMed ID: 32639095
[TBL] [Abstract][Full Text] [Related]
8. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
[TBL] [Abstract][Full Text] [Related]
9. Model Based Estimation of Posaconazole Tablet and Suspension Bioavailability in Hospitalized Children Using Real-World Therapeutic Drug Monitoring Data in Patients Receiving Intravenous and Oral Dosing.
Kane Z; Cheng I; McGarrity O; Chiesa R; Klein N; Cortina-Borja M; Standing JF; Gastine S
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0007723. PubMed ID: 37260401
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
Groll AH; Abdel-Azim H; Lehrnbecher T; Steinbach WJ; Paschke A; Mangin E; Winchell GA; Waskin H; Bruno CJ
Int J Antimicrob Agents; 2020 Sep; 56(3):106084. PubMed ID: 32682946
[TBL] [Abstract][Full Text] [Related]
11. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.
Oh J; Kang CI; Kim SH; Huh K; Cho SY; Chung DR; Lee SY; Jung CW; Peck KR
Mycoses; 2020 Jan; 63(1):89-94. PubMed ID: 31610064
[TBL] [Abstract][Full Text] [Related]
12. Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients.
Ju C; Lian Q; Chen A; Zhao B; Zhou S; Cai Y; Xie H; Wei L; Li S; He J
Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36036471
[TBL] [Abstract][Full Text] [Related]
13. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
Arrieta AC; Sung L; Bradley JS; Zwaan CM; Gates D; Waskin H; Carmelitano P; Groll AH; Lehrnbecher T; Mangin E; Joshi A; Kartsonis NA; Walsh TJ; Paschke A
PLoS One; 2019; 14(3):e0212837. PubMed ID: 30913226
[TBL] [Abstract][Full Text] [Related]
14. Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals.
Heimann SM; Penack O; Heinz WJ; Rachow T; Egerer G; Kessel J; Claßen AY; Vehreschild JJ
Int J Infect Dis; 2019 Jun; 83():130-138. PubMed ID: 30978465
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for subtherapeutic levels of posaconazole tablet.
Tang LA; Marini BL; Benitez L; Nagel JL; Miceli M; Berglund C; Perissinotti AJ
J Antimicrob Chemother; 2017 Oct; 72(10):2902-2905. PubMed ID: 29091205
[TBL] [Abstract][Full Text] [Related]
16. Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents.
Tragiannidis A; Herbrüggen H; Ahlmann M; Vasileiou E; Gastine S; Thorer H; Fröhlich B; Müller C; Groll AH
J Antimicrob Chemother; 2019 Dec; 74(12):3573-3578. PubMed ID: 31504563
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease.
McCann S; Sinha J; Wilson WS; McKinzie CJ; Garner LM; Gonzalez D
Clin Pharmacokinet; 2023 Jul; 62(7):997-1009. PubMed ID: 37179512
[TBL] [Abstract][Full Text] [Related]
18. [Use of posaconazole in children: Experience in a tertiary pediatric hospital].
Rosanova MT; Voto C; Mussini MS; Sarkis C; Gómez S; Sberna N; Carnovale S; Caracciolo B; Lede R
Arch Argent Pediatr; 2018 Jun; 116(3):e451-e454. PubMed ID: 29756722
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review.
Jancel T; Shaw PA; Hallahan CW; Kim T; Freeman AF; Holland SM; Penzak SR
J Clin Pharm Ther; 2017 Feb; 42(1):75-79. PubMed ID: 27982447
[TBL] [Abstract][Full Text] [Related]
20. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]